Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, multi-center Phase II trial using IL-15 super-agonist complex (N-803
formerly known as Alt-803) maintenance after allogeneic hematopoietic cell transplant
(alloHCT) for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).